HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $28 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Matthew Caufield has reiterated a Buy rating on Phathom Pharmaceuticals (NASDAQ:PHAT) and maintained a $28 price target.
July 19, 2024 | 10:41 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Matthew Caufield has reiterated a Buy rating on Phathom Pharmaceuticals and maintained a $28 price target.
The reiteration of a Buy rating and the maintenance of a $28 price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100